Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Treated With Immune Checkpoint Inhibitors for Various Cancers
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
- 试验地点
- 6
- 主要终点
- Progression Free Survival
研究概览
简要总结
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
详细描述
Immune checkpoint inhibitors have been shown to increase survival in metastatic solid tumor patients when compared to the previously standard of care chemotherapy. Epidemiologic studies of American Indian cancer patients demonstrated having significantly worse survival when compared with Caucasians when controlled for age, sex, alcohol abuse, smoking, insurance, and disease stage.
There are no current studies specifically examining the American Indian population receiving treatment with immune checkpoint inhibitors. The aim is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •above age 18,
- •histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used
- •received immunotherapy as part of their treatment
- •Self-identified American Indian in ethnicity
- •Patients at the Stephenson Cancer Center between 2015 to 2021
排除标准
- •patients who did not receive immune checkpoint inhibitor therapy
研究组 & 干预措施
American Indian population
干预措施: Immunotherapy (Biological)
Caucasians treated with immunotherapy
干预措施: Immunotherapy (Biological)
结局指标
主要结局
Progression Free Survival
时间窗: 1 year
Evaluating progression free survival of American Indian population vs. White population who were treated with immunotherapy
Overall Survival Benefit
时间窗: 1 year
Evaluating the overall survival benefit of American Indian population vs. white population who were treated with immunotherapy
Treatment related Adverse Events
时间窗: 1 year
Evaluating treatment related adverse events of American Indian population vs. white population who were treated with immunotherapy
次要结局
- Difference in cancer related mortality(1 year)